Carbonic anhydrase (CA), a well-characterized metalloenzyme, is associated with oxygen-18 ( 18O)-isotopic fractionations of CO2. To investigate how CA activity links the 18O of breath CO2 to pre-diabetes (PD) and type 2 diabetes (T2D) during metabolism, we studied pre- and post-dose CA activities in erythrocytes with simultaneous monitoring of 18O/ 16O-isotope ratios of breath CO2 and thereafter elucidated potential metabolic pathways underlying CA alteration in the pathogenesis of T2D. Here we show that the post-dose CA activity in both T2D and PD was markedly enhanced, whereas the non-diabetic controls (NDC) exhibited a considerable reduction in post-dose CA activity when compared with their basal CA activities. However, T2D and PD exhibited isotopic enrichments of 18O in breath CO2, while a marked depletion of 18O in CO2 was manifested in NDC. Thus, the isotopic enrichments and depletions of 18O in breath CO2 were well correlated with the changes in CA activities for controls, PD and T2D. Our findings suggest the changes in CA activities in erythrocytes may contribute to the pathogenesis of T2D and the breath C 18O 16O regulated by the CA activity as a potential biomarker for non-invasive assessment of T2D and thus may open a new method for treating T2D.
Carbonic anhydrase (CA), a well-characterized pH-regulatory metalloenzyme found in most tissues including human erythrocytes (red blood cells), rapidly catalyzes the hydration of carbon dioxide (CO2) to form bicarbonate (HCO3−) and the reversible dehydration1,2. It also plays an important role in the transport of CO2 and ions (such as H+, Na+ and Cl−) along with pH-regulation in a variety of physiological processes ranging from respiration to intermediary metabolism at the cellular level3,4,5. Some early evidences suggest that the changes in CA activities in erythrocytes may be an initial step of altered metabolism in diabetes mellitus2,6. However, the precise role of CA activity, especially in the pathogenesis of type 2 diabetes mellitus (T2D), the most common deleterious metabolic disease at present worldwide7, is not currently known. Furthermore, the potential links between CA activity and T2D have not yet been fully elucidated.
Some early studies8,9,10 demonstrated that the oxygen-16 ( 16O) isotope in 12C 16O2 and the oxygen-18 ( 18O) isotope of body water (H2 18O) are rapidly exchanged during the respiration process in humans, catalyzed by carbonic anhydrase. This efficient exchange suggests the possibility of exploiting the oxygen-isotope fractionations of CO2 in exhaled breath for non-invasive assessment of early-stage pre-diabetes prior to the onset of T2D. It also suggests a tantalizing hypothesis that monitoring stable 18O/16O isotope ratios of breath CO2 in response to CA activity may track the pathogenesis of the preclinical phase of T2D and hence may introduce a new strategy for treating T2D. Moreover, unravelling the exact metabolic pathways involved in causing the isotopic changes of 12C 16O 18O/12C 16O 16O in breath influenced by the enzymatic activity of CA in erythrocytes remains a challenge, whenever an individual is at high-risk for altered insulin action or for the acute onset of T2D.
In this study, we first investigated whether the total enzymatic activity of CA in erythrocytes is altered when individuals are in pre-diabetic and T2D states and subsequently we assessed the precise role of CA activity in erythrocytes in response to glucose-stimulated insulin secretion that might influence the change in oxygen-isotope fractionations of CO2 in exhaled breath. We further explored the potential metabolic pathways underlying CA alteration in the pathogenesis of T2D and the mechanisms linking breath oxygen-isotopes to pre-diabetes (PD) and T2D.
Results and Discussion
To investigate the potential role of CA in the pathogenesis of T2D, we first tested whether the total basal CA activity altered in the pre-diabetic state and T2D after overnight fasting. We measured the total erythrocytes CA activity, which includes primarily three isozymes of CA (i.e. CAI, CAII and CAIII), spectro-photometrically in patients with non-diabetic controls (NDC) (n = 32), pre-diabetes (PD) (n = 39) and T2D (n = 48). In this investigation (Fig. 1a), individuals with T2D exhibited significantly lower basal CA activity as compared with PD and NDC, whereas no significant difference in basal CA activities was evident between subjects with PD and NDC. Several lines of evidence suggest that glycosylation of CA decreases its enzymatic and immunological activities and the glycosylation of CA is also enhanced during the peripheral circulation of erythrocytes2,6. Therefore, the decrease in basal CA activity for T2D individuals is possibly attributed to the increased level of glycosylation of the enzyme, caused by the exposure of erythrocytes to a higher concentration of plasma glucose compared to the PD and NDC (see Supplementary Fig. 1). Taken together, these findings indicate that the glycosylation plays a vital role in reduction of CA activity in individuals with T2D, whereas the glycosylation of CA does not play a significant role in either causing or facilitating the considerable differences in basal CA activities when an individual is in a normal or pre-diabetic state owing to their slight difference in blood glucose levels. Moreover, our results are coincidence with the previous study11, where the both CA I isozyme levels and total erythrocytes CA activities in fasting state have been reported to be downregulated in T2D as compared to control individuals.
We next explored the effect of CA activity in erythrocytes after administration of glucose, as the potential role of CA in response to glucose ingestion for NDC, PD and T2D remains unknown. To investigate this, we performed the 2h-oral glucose tolerance test (2h-OGTT). The post-dose CA activity (Fig. 1b), in both T2D and PD individuals, was markedly enhanced as compared with that of basal CA activity, although no significant difference of CA activities between these two groups was evident. In contrast, the NDC individuals exhibited a considerable reduction in post-dose CA activity when compared with basal CA activity. Erythrocyte receptor bound insulin has been proposed to alter the carbonic anhydrase activity12, suggesting that post-dose glucose stimulated plasma insulin levels may play an important role in changing the post-dose CA activities in erythrocytes in NDC, PD and T2D.
It is noteworthy that only pre-dose or post-dose erythrocyte CA activities do not allow one to distinguish the exact pathological state of the diabetes mellitus. We therefore, examined the absolute changes in CA activities (i.e. ΔCA) between the pre-dose (basal) and post-dose of glucose ingestion among all individuals (Fig. 2c). We found marked differences in ΔCA activities between subjects with NDC and PD and subjects with PD and T2D, suggesting a potential link between changes in CA activities and altered metabolism responsible in individuals with PD and T2D. We have also established the previous hypothesis that the changes in CA activities in erythrocytes might signify the onset of altered metabolism in diabetes mellitus2. In view of this result, our findings suggest ΔCA activity in erythrocytes may contribute to the pathogenesis of T2D and might be considered as a potential biomarker for the detection of T2D.
We next investigated the oxygen-isotope fractionations of CO2 by monitoring the 18O/16O stable isotope ratios in exhaled breath, expressed as delta-over-baseline (DOB) relative to the Vienna Pee Dee Belemnite standard, i.e., δDOB 18O‰ = [(δ 18O‰)t = t - (δ 18O‰)t = basal], associated with CA activities. To explore whether the changes in CA activities are associated with changes in 18O/16O isotope ratios of breath CO2, we investigated the excretion kinetics of δDOB 18O‰ values in breath samples from NDC, PD and T2D (Fig. 2a), using an optical cavity-enhanced integrated cavity output spectrometer. In this investigation, individuals with T2D exhibited significantly higher isotopic enrichments of 18O in CO2 compared with PD during the 2h-OGTT, while a marked depletion of 18O in CO2 was manifested in individuals with NDC (Fig. 2b). These outcomes suggest oxygen-isotope fractionations of CO2 in breath play an important role for non-invasive assessment of diabetes mellitus and hence these findings may open a new route to treat diabetes mellitus. However, the observations of isotopic depletion of 18O in CO2 for NDC and enrichments of 18O in CO2 for both individuals with T2D and PD are likely to be the effects of inhibition and promotion of catalytic activities of CA respectively, thus unveiling a potential link between CA activity in erythrocytes and the 18O-isotopic exchange in exhaled breath. As a result, we therefore posit that the monitoring of 18O-exchange between carbon dioxide (C 16O2) and body water (H2 18O) influenced by the enzymatic activity of CA may distinctively track the evolution of pre-diabetes prior to the onset of T2D in a non-invasive way (Fig. 3a).
To investigate the precise transition from normal to pre-diabetes and then on to type 2 diabetes, we determined optimal diagnostic cut-off points of δDOB 18O‰ values in breath and ΔCA activity in erythrocytes using receiver operating characteristics curve (ROC) analysis (Fig. 3b and 3c). Individuals with δDOB 18O‰ > 2.77‰ and δDOB 18O‰ < −1.14‰ were considered T2D and NDC respectively, whereas subjects with 2.77 ≥ δDOB 18O‰ ≥ −1.14 were suggested to be PD and these corresponded to the diagnostic sensitivity and specificity of ~95% and ~91%, respectively. Conversely, a diagnostic cut-off point of ΔCA = 3.15 U/min/mL between individuals with PD and T2D, exhibited the sensitivity and specificity of 91.7% and 94.9%, respectively, whereas ΔCA = −1.31 U/min/mL correctly diagnosed individuals with NDC and PD corresponding to similar levels of diagnostic sensitivity and specificity. Taken together, these findings may have a broad clinical efficacy for accurate evaluation of diabetes mellitus either invasively or non-invasively and therefore provide a unique approach to treat the world's most common metabolic disease.
Finally, we elucidated the potential metabolic pathways (Fig. 4) both in basal and postprandial (2h-OGTT) states underlying the mechanisms responsible for the alteration of CA activity and 18O-isotopic exchange in breath CO2. Under basal conditions, the majority of endogenous glucose disposal takes place in insulin-independent tissues like the brain, liver and gastrointestinal tract13,14. In T2D state, an elevated rate of hepatic glucose production is the major abnormality for the increased basal plasma glucose concentration14,15,16 and erythrocytes are then exposed to excessive glucose concentration which in turn makes a higher glycosylated form of CA than that in healthy individuals, resulting in reduction of total enzymatic activity of CA. However, in the basal state, more than 60% of cellular fuel for insulin-dependent muscle tissues is derived from free fatty acids for whole-body fuel oxidation17. The major metabolite CO2 produced by cellular oxidation reaches erythrocytes through the bloodstream and reacts with body water to form carbonic acid (H2CO3). The isotopes 16O of 12C 16O2 and 18O of H2 18O are rapidly exchanged, catalyzed by CA activity, leading to the generation of H2C 18O 16O2 together with H2C 16O 16O2. All these carbonic acids rapidly degas to produce both C 18O 16O and C 16O 16O which subsequently bind to haemoglobin molecules to form carbaminohemoglobin compounds (Hb.CO2), which are then transported to the lungs where 12C 16O 18O and 12C 16O 16O are excreted in exhaled breath.
However, under postprandial condition, the exogenous glucose stimulates the release of insulin which facilities the majority of ingested glucose to uptake predominantly in peripheral tissues18 through the GLUT 4 transporter and a small fraction to adipose tissue. For T2D, the inhibition of insulin-receptor signalling due to insulin resistance and accordingly the lack of GLUT 4 recruitment plays a central role for the blunted rate of glucose transportation especially in insulin-dependent muscle tissues15. After glucose enters into muscle cell, it is phosphorylated to produce glucose-6-phosphate which later equilibrates between glycogenesis and glycolytic metabolic pathways. About one-third of the total glucose-6-phosphate, which enters into the glycolytic pathway, is predominantly oxidised into CO2 which is then transported to the erythrocyte and eventually excreted as 12C 16O 18O and 12C 16O 16O in breath. In case of pre-diabetes and newly diagnosed type 2 diabetes, the pancreas produces more insulin to compensate the insulin resistance. Therefore, erythrocyte is exposed to the environment of elevated receptor bound insulin in pre-diabetes and newly diagnosed type 2 diabetes, creating an ionic imbalance within the erythrocytes owing to increased proton production, Na+ ion uptake and possibly exchange of other ions such as K+ and Cl− between plasma and erythrocytes2,12, leading to the enhancement of CA activity and accordingly alter the 18O-isotopic fractionations of CO2 in breath.
In conclusion, our findings point to a fundamental mechanism underlying the cause of altered CA activity in erythrocytes in individuals with dysglycemia. We have also taken a step towards unravelling the potential link between erythrocyte CA activity and 18O-isotopic fractionations of breath CO2, thus suggesting that 18O in CO2, the major metabolite of human breath, could be used as a potential molecular biomarker for the identification of accurate metabolic transition from normal to pre-diabetes and then on to type 2 diabetes in a non-invasive approach. Although many important gaps remain in our understanding of the exact metabolic pathways involved in causing the 18O-isotopic exchange and in the pathophysiology of T2D, our findings may open new perspectives in the molecular diagnosis of diabetes mellitus with broad clinical applications. Moreover, new insights into the mechanisms linking changes in CA activities to 18O-isotopic exchange are fostering exploration of the molecular basis of the pathogenesis of type 2 diabetes and new methods along with new pharmacological targets to prevent or treat the deleterious effects of this metabolic disease that threatens modern society.
119 participants (n = 32 non-diabetic control, n = 39 pre-diabetes, n = 48 type 2 diabetes) were selected for the study. Individuals with hypertension, chronic respiratory disorder, interstitial lung disease, asthma or taking any type of medication that may alter the glucose metabolism are strictly excluded from the present study. Members from families with previous history of diabetes were also excluded from the study. Subjects were classified into three groups of type 2 diabetes (T2D), pre-diabetes (PD) and non-diabetic controls (NDC) according to the current criteria outlined by the American Diabetes Association19. Individuals with T2D were determined with glycosylated hemoglobin (HbA1c %) ≥ 6.5 and 2 hr glucose ≥ 200 mg/dL during an oral glucose tolerance test (OGTT), whereas PD was determined with 5.7 ≤ HbA1c (%) < 6.5 and 140 mg/dL ≤ 2 hr OGTT glucose < 200 mg/dL. Non-diabetic controls were defined with normal glucose tolerant, with 5.7 > HbA1c (%) and 2-hr OGTT glucose <140 mg/dL. The detailed subject characteristics are presented in Table 1. Informed consents were obtained from all participants according to the protocol approved by Institutional Ethics Committee of Post Graduate Medical Education & Research (IPGMER), Kolkata (Memo No. Inst/IEC/275) and the methods were carried out in accordance with the approved guidelines. All experimental protocols were also approved by the S.N. Bose Centre, Kolkata (Ref. No: SNB/PER-2-6001/13-14/1769).
After overnight fasting (~12 hours), subjects were placed on chairs and a baseline breath sample from each subject was taken in a breath sample collection bag (QUINTRON, USA, SL No.QT00892). A baseline blood sample (10 mL) was also collected simultaneously. A test meal containing 75-gm normal glucose dissolved in 150-mL water was orally administered and consumed within 1 minute. From this starting point, breath samples were collected in every 30-min interval, whereas blood samples were drawn after 2-hr of glucose load. During exhalation, subjects were instructed in such a way that they breathed normally, held for a few seconds and exhaled completely into a breath sample collection bag so that the oral breath first passed to dead space and the endogenously produced deep-breath (end expiratory breath) entered into the 750 mL reservoir bag through an one-way valve. The blood samples were utilized for measurement of glycated hemoglobin i.e. HbA1c (%), carbonic anhydrase activities and insulin levels. Breath samples were immediately analyzed to measure δ 18O of breath CO2.
Plasma Glucose concentrations were measured spectrophotometrically (2300 STAT Plus Glucose Analyzer). Insulin concentrations were measured by using monoclonal antibody coated immunoassay DIAsource INS-EASIA Kits (DIAsource ImmunoAssays S. A. Rue du Bosquet, 2, B-1348 Louvain-la-Neuve, Belgium). HbA1c (%) was determined in HPLC method by utilizing an HbA1c analyzer (D-10, USA).
Breath sample analysis
Breath samples were drawn from the breath sample bags by an air-tight syringe (QUINTRON) through a T-connector fitted onto the reservoir bag. All breath samples were analyzed by a high-resolution isotopic CO2 integrated cavity output spectrometer (ICOS).
Integrated Cavity Output Spectrometer
The cavity-enhanced absorption spectroscopy is an important tool for the measurement of trace gases along with isotopic species with ultra low concentrations. We utilized a high-resolution carbon dioxide isotope analyzer based on off-axis integrated cavity output spectroscopy (ICOS) exploiting a cavity-enhanced laser absorption technique to measure the isotopic compositions of CO2 of breath samples. There are few naturally occurring isotopes of carbon dioxide among which 12C 16O 16O and 13C 16O 16O are most abundant isotopes of CO2. The oxygen-18 isotope, i.e. 12C 16O 18O, is the stable third major naturally occurring isotope of CO2. The capability of the ICOS technique in comparison to conventional isotope ratio mass spectrometry (IRMS) to measure the stable isotope ratios of carbon dioxide ( 12C 16O 16O, 13C 16O 16O and 12C 16O 18O) has been well demonstrated elsewhere20,21. The ICOS instrument is so designed that laser light can be directed into the off-axis of the optical cavity. The present ICOS spectrometer (CCIA 36-EP, Los Gatos research, USA) consists of a continuous wave distributed feedback diode laser operating at ~2.05 μm and a high-finesse optical cavity (~59 cm long) with two high-reflectivity mirrors (R ~ 99.98%) at the ends of the measurement cell. This arrangement allows the laser light to move back and forth inside the cavity to reach an effective optical path-length of ~3 km and thus enabling high sensitivities. The laser frequency was repeatedly tuned to scan over 20 GHz across the P(36), R(28) and P(16) ro-vibrational lines to record the absorption spectra of 12C 18O 16O, 12C 16O 16O and 13C 16O 16O at the wave numbers of 4874.178 cm−1, 4874.448 cm−1 and 4874.086 cm−1 respectively, in the (2,0°,1) ← (0,0°,0) vibrational combination band of the CO2 molecule22. The transmitted laser intensities were recorded by exploiting a photodetector after passing through a breath sample of interest. Absorption was determined from the measurement of voltage from photodetector. Beer-Lambert law was utilized to calculate the concentration after integrating the absorption spectrum. The data were acquired at a rate of 1 Hz. The temperature of the cavity was maintained at 46°C by a resistive heater and feedback control system. The pressure of the cavity also regulated at 30 Torr by a diaphragm pump and solenoid valve in order to analyze the sample. The 12C 18O 16O enrichments in the breath samples have been expressed by the conventional notation, δ 18O in per mil (‰) relative to the standard Pee Dee Belemnite (PDB). It is described as below:
δ 18O‰ = (Rsample/Rstandard − 1) × 1000, where Rsample is the 18O/16O isotope ratio of the sample and Rstandard is the international standard Vienna Pee Dee Belemnite value i.e. 0.0020672. The accuracy and precision for the δ 18O‰ measurements of the breath samples were determined by using a standard NOAA air tank. Accuracy was determined from the measurements of seven flasks filled from the certified standard NOAA air tank (Supplementary Table 1), whereas precision was determined from six consecutive measurements of same breath sample (Supplementary Table 2). We have determined that the typical precision of δDOB 18O ‰ [(δ 18O ‰)2h post-dose − (δ 18O ‰)pre-dose] measurements is ±0.18‰ in our current study.
Blood sample preparation
10 mL of venous blood samples were collected from each participant in EDTA vacutainer tubes. The collected blood samples were centrifuged at 2000 r.p.m for 15 minutes. Plasma was isolated and buffy coat was removed. The red blood cells (RBC) were washed with 0.9% NaCl solution and allowed to spin against 4000 r.p.m for 20 minutes. The erythrocytes were lysed with ice-cold distilled water. The hemolysate was centrifuged at 10,000 r.p.m for 30 minutes to remove the ghost cells and the supernatant liquid was collected. The fresh supernatant liquid was used for analysis of carbonic anhydrase activity.
Total erythrocyte carbonic anhydrase measurement
The esterase activity of carbonic anhydrase was determined spectro-photometrically as mentioned by Armstrong et al.23 with the modification described by Parui et al.12. In this assay, the esterase activity of carbonic anhydrase was determined spectro-photometrically from the hydrolysis rate of p-nitrophenyl acetate to p-nitrophenol. As the other esterases present in the hemolysate also hydrolyze the p-nitrophenyl acetate, a specific inhibitor of CA, acetazolamide was used and the acetazolamide-sensitive activity was taken as the net CA activity. This was performed from the differences between the absorbances before and after adding inhibitor. The protocol consisted of 100 μL hemolysate placed in 1 cm spectrometric cell containing 1.9 mL Tris buffer and 1 ml p-nitrophenyl acetate. The change of absorbance was measured over the period of 3 min at 348 nm before and after adding the hemolysate. The same measurements were performed in the presence of 0.1 mM acetazolamide inhibitor. The absorbance was measured by a UV-Vis spectrophotometer (Shimadzu UV-2600 Spectrophotometer). One unit of enzyme activity was expressed as μmol of p-nitrophenol relased/min/mL from hemolysate at room temperature (25°C)2,12.The following formula was used to calculate total erythrocyte CA activity:
where A3 is absorbance after 3 min, A0 is the absorbance at 0 min, 5 × 103 M−1cm−1 is the molar absorptivity of p-nitrophenol. The activity was normalized to 4.5 × 109 cells/mL.
Statistical analyses were performed using Origin Pro 8.0 (Origin Lab Corporation, USA) and Analyse-it Method Evaluation software (Analyse-it Software Ltd, UK, version 2.30). To compare normally distributed data, one way analysis of variance (ANOVA) was used whereas non-normal distributed data were analyzed by the Kruskal-Wallis test and Mann-Whitney test. A two sided p-value less than 0.05 was considered as statistically significant. All results were expressed as mean ± SEM except Fig. 3a, where values are mean ± SD. Receiver operating characteristic curves (ROC) were generated by plotting sensitivity (true positive rate) vs 1-specificity (false positive rate) to obtain the different cut-off points of δDOB 18O‰ values and ΔCA activities (Supplementary Table 4-Supplementary Table 7). The optimal cut-off value was considered to be that point which maximized the sensitivity and specificity (Supplementary Table 8). Data from insulin measurement were analyzed by MasterPlex software (Hitachi Software Engineering America, South San Francisco, CA, USA).
Kendall, A. G. & Tashian, R. E. Erythrocyte carbonic anhydrase I: Inherited deficiency in humans. Science 197, 471–472 (1977). 10.1126/science.406674.
Gambhir, K. K., Oates, P., Verma, M., Temam, S. & Cheatham, W. High fructose feeding enhances erythrocyte carbonic anhydrase 1 mRNA levels in rat. Ann. N. Y. Acad. Sci. 827, 163–169 (1997).
Enns, T. Facilitation by carbonic anhydrase of carbon dioxide transport. Science 155, 44–47 (1967).
Henry, R. P. Multiple roles of carbonic anhydrase in cellular transport and metabolism. Annu. Rev. Physiol. 58, 523–538 (1996).
Zanconato, S., Cooper, D. M., Armon, Y. & Epstein, S. Effect of increased metabolic rate on oxygen isotopic fractionation. Respiration Physiology 89, 319–327 (1992).
Kondo, T. et al. Estimation and characterization of glycosylated carbonic anhydrase I in erythrocytes from patients with diabetes mellitus. Clinica Chimica Acta 116, 227–236 (1987).
Zimmet, P., Alberti, K. G. M. M. & Shaw, J. Global and societal implications of the diabetes epidemic. Nature 414, 782–787 (2001). 10.1038/414782a.
Epstein, S. & Zeiri, L. Oxygen and carbon isotopic compositions of gases respired by humans. Proc. Natl. Acad. Sci. USA. 85, 1727–1731 (1988).
Forster, R. E., Gros, G., Lin, L., Ono, Y. & Wunder, M. The effect of 4, 4*-diisothiocyanato-stilbene-2, 2*-disulfonate on CO2 permeability of the red blood cell membrane. Proc. Natl. Acad. Sci. USA. 95, 15815–15820 (1998).
Gillon, J. & Yakir, D. Influence of carbonic anhydrase activity in terrestrial vegetation on the 18O content of atmospheric CO2 . Science 291, 2584–2587 (2001).
Gambhir, K. K., Ornasir, J., Headings, V. & Bonar, A. Decreased total carbonic anhydrase esterase activity and decreased levels of carbonic anhydrase 1 isozyme in erythrocytes of type II diabetic patients. Biochemical Genetics 45, 431–439 (2007). 10.1007/s10528-007-9086-x.
Parui, R., Gambhir, K. K. & Mehrotra, P. P. Changes in carbonic anhydrase may be the initial step of altered metabolism in hypertension. Biochem. Int. 23, 779–789 (1991).
Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–846 (2006).
DeFronzo, R. A. Pathogenesis of type 2 diabetes mellitus. Med. Clin. N. Am. 88, 787–835 (2004). 10.1016/j.mcna.2004.04.013.
Orme, C. M. & Bogan, J. S. Sorting out diabetes. Science 324, 1155–1156 (2009).
Rothman, D. L., Magnusson, I., Katz, L. D., Shulman, R. G. & Shulman, G. I. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 254, 573–576 (1991). 10.1126/science.1948033.
Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799–806 (2001). 10.1038/414799a.
Lowell, B. B. & Shulman, G. I. Mitochondrial dysfunction and type 2 diabetes. Science 307, 384–387 (2005). 10.1126/science.1104343.
Ghosh, C. et al. Non-invasive 13C-glucose breath test using residual gas analyzer-mass spectrometry: a novel tool for screening individuals with pre-diabetes and type 2 diabetes. J. Breath Res. 8(3), 036001 (2014). 10.1088/1752-7155/8/3/036001.
Barker, S. L. L., Dipple, G. M., Dong, F. & Baer, D. S. Use of laser spectroscopy to measure the 13C/12C and 18O/16O compositions of carbonate minerals. Anal. Chem. 83, 2220–2226 (2011). 10.1021/ac103111y.
Crosson, E. R. et al. Stable isotope ratios using cavity-ring-down spectroscopy: determination of 13C/12C for carbon dioxide in human breath. Anal. Chem. 74, 2003–2007 (2002). 10.1021/ac025511d.
Maity, A. et al. Oxygen-18 stable isotope of exhaled breath CO2 as a non-invasive marker of Helicobacter pylori infection. J. Anal. At. Spectrom. 29, 2251–2255 (2014). 10.1039/C4JA00280F.
Armstrong, J. McD., Myers, D. V., Verpoorte, J. A. & Edsall, J. T. Purification and properties of human erythrocyte carbonic anhydrases. J. Biol. Chem. 241, 5137–5149 (1966).
The study was supported by the Department of Biotechnology (DBT, India) for the award of Rapid Grant for Young Investigators (No. BT/PR6683/GBD/27/477/2012) to Dr. Manik Pradhan to initiate breath analysis research work on diabetes. Authors would like to thank Prof. Richard N. Zare (Stanford University, USA) and Prof. Andrew Orr-Ewing (University of Bristol, UK) for reviewing this manuscript in detail and for useful discussion. Authors further thank to Prof. Dr. Sasanka Chakraborty (IPGMER, Kolkata) and Dr. Subhankar Kumar (IPGMER, Kolkata) for providing useful suggestions. The authors (C. Ghosh and S. Som) also acknowledge S. N. Bose Centre for PhD fellowship, whereas A. Maity and G. D. Banik thank to the Department of Science & Technology (DST, India) for Inspire Fellowships.
The authors declare no competing financial interests.
Electronic supplementary material
About this article
Cite this article
Ghosh, C., Banik, G., Maity, A. et al. Oxygen-18 isotope of breath CO2 linking to erythrocytes carbonic anhydrase activity: a biomarker for pre-diabetes and type 2 diabetes. Sci Rep 5, 8137 (2015). https://doi.org/10.1038/srep08137
This article is cited by
Proceedings of the National Academy of Sciences, India Section A: Physical Sciences (2018)
A broadband Tm/Ho-doped fiber laser tunable from 1.8 to 2.09 µm for intracavity absorption spectroscopy
Applied Physics B (2018)
Insulin sensitivity index (ISI0, 120) potentially linked to carbon isotopes of breath CO2 for pre-diabetes and type 2 diabetes
Scientific Reports (2015)
Scientific Reports (2015)